Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

HPV Prevalence and Genotype Distribution Among Women From Hengyang District of Hunan Province, China.

Tytuł:
HPV Prevalence and Genotype Distribution Among Women From Hengyang District of Hunan Province, China.
Autorzy:
Tang SY; Institute of Pathogenic Biology, School of Basic Medicine Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Liao YQ; Institute of Pathogenic Biology, School of Basic Medicine Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Hu Y; Institute of Pathogenic Biology, School of Basic Medicine Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Shen HY; Institute of Pathogenic Biology, School of Basic Medicine Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Wan YP; Institute of Pathogenic Biology, School of Basic Medicine Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Wu YM; Institute of Pathogenic Biology, School of Basic Medicine Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Źródło:
Frontiers in public health [Front Public Health] 2021 Nov 05; Vol. 9, pp. 710209. Date of Electronic Publication: 2021 Nov 05 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Lausanne : Frontiers Editorial Office
MeSH Terms:
Papillomavirus Infections*/complications
Papillomavirus Infections*/epidemiology
Papillomavirus Infections*/prevention & control
China/epidemiology ; Female ; Genotype ; Humans ; Middle Aged ; Prevalence ; Retrospective Studies
References:
Zhonghua Zhong Liu Za Zhi. 2018 Oct 23;40(10):757-763. (PMID: 30392340)
Vaccine. 2018 Jun 18;36(26):3820-3829. (PMID: 29778519)
Braz J Med Biol Res. 2016;49(6):e5254. (PMID: 27254662)
J Reprod Med. 2014 Jan-Feb;59(1-2):44-50. (PMID: 24597286)
Br J Cancer. 2006 Dec 4;95(11):1593-7. (PMID: 17088908)
Int J Cancer. 2010 Dec 15;127(12):2893-917. (PMID: 21351269)
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 May 6;52(5):493-497. (PMID: 29747341)
BMC Infect Dis. 2019 May 8;19(1):390. (PMID: 31068141)
J Clin Lab Anal. 2018 Oct;32(8):e22581. (PMID: 29862560)
mSphere. 2018 May 2;3(3):. (PMID: 29720524)
Health Equity. 2019 May 28;3(1):254-263. (PMID: 31289786)
Asian Pac J Cancer Prev. 2011;12(5):1149-53. (PMID: 21875257)
Biomed Res Int. 2015;2015:314815. (PMID: 26819950)
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. (PMID: 23199955)
Br J Cancer. 2006 Jul 3;95(1):96-101. (PMID: 16773069)
BMC Cancer. 2018 May 15;18(1):562. (PMID: 29764400)
J Infect Dis. 2005 Jun 1;191(11):1796-807. (PMID: 15871111)
J Ark Med Soc. 2013 Jan;109(8):160-3. (PMID: 23367687)
Lancet Infect Dis. 2007 Jul;7(7):453-9. (PMID: 17597569)
Mol Biol Rep. 2011 Oct;38(7):4715-21. (PMID: 21132533)
Int J Cancer. 2006 Dec 1;119(11):2677-84. (PMID: 16991121)
Turk J Gastroenterol. 2018 Mar;29(2):157-163. (PMID: 29749321)
Iran J Pathol. 2017 Winter;12(1):35-44. (PMID: 29760751)
J Community Health. 2013 Oct;38(5):907-10. (PMID: 23653161)
Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2655-64. (PMID: 20719907)
Vaccine. 2008 Aug 19;26 Suppl 10:K1-16. (PMID: 18847553)
Virology. 2013 Oct;445(1-2):2-10. (PMID: 23683837)
Infect Dis Obstet Gynecol. 2019 Mar 24;2019:4376902. (PMID: 31019362)
Virol J. 2012 Aug 08;9:153. (PMID: 22873487)
J Hum Genet. 2011 Apr;56(4):313-5. (PMID: 21307859)
Zhonghua Fu Chan Ke Za Zhi. 2009 Dec;44(12):898-902. (PMID: 20193415)
Virol J. 2010 Mar 23;7:66. (PMID: 20307327)
J Med Virol. 2016 Mar;88(3):532-40. (PMID: 26266484)
Lancet. 2005 Sep 17-23;366(9490):991-8. (PMID: 16168781)
Gynecol Oncol. 2009 Sep;114(3):501-5. (PMID: 19541348)
J Med Virol. 2015 Nov;87(11):1966-72. (PMID: 26073652)
Rev Med Inst Mex Seguro Soc. 2015;53 Suppl 2:S162-4. (PMID: 26462511)
Int J Cancer. 2012 Feb 1;130(3):641-52. (PMID: 21387308)
Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Apr;34(4):399-403. (PMID: 23937850)
Zhonghua Zhong Liu Za Zhi. 2018 Apr 23;40(4):241-246. (PMID: 29730908)
Gynecol Oncol. 2006 Apr;101(1):40-5. (PMID: 16256180)
Contributed Indexing:
Keywords: cervical cancer; distribution; genotype; human papillomavirus; prevalence
Entry Date(s):
Date Created: 20211122 Date Completed: 20220401 Latest Revision: 20220531
Update Code:
20240105
PubMed Central ID:
PMC8602211
DOI:
10.3389/fpubh.2021.710209
PMID:
34805062
Czasopismo naukowe
Most cervical cancers were closely associated with human papillomavirus (HPV) infections. Therefore, understanding the ecological diversity of HPV prevalence and genotype distribution among various populations in different geographical regions was essential for optimizing HPV vaccination and maximizing the vaccination effects. A total of 12,053 patient data from the three-level hospitals in Hengyang city were retrospectively analyzed. In this study, the HPV prevalence was 10.16% overall, and the multiple-type infection rate was 1.83%. The HR-HPV infection rate was 8.52%. The top six HPV genotypes were as follows in descending order: HPV16, HPV58, HPV52, HPV39, HPV51, and HPV53. The HPV prevalence in the group above 60 years old was the most, and their HR-HPV infection rate corresponded to the most too. The infection rates of HPV and HR-HPV among outpatients were both lower than those among the hospitalized-patients, respectively. Among the hospitalized-patients, the infection rates of HPV and HR-HPV among the 50-60 years group were the most in both. The HR-HPV ratio-in-positive among HPV-positive patients with the histopathologic examination was higher than that among those patients without. Among 52 HPV-positive patients with cervical squamous carcinoma, the ratio-in-positive of HPV16 was 61.54%. This study demonstrated that the HPV prevalence varied with age among women from Hengyang district of Hunan province in China and showed that HPV16, HPV58, HPV52, HPV39, HPV51, and HPV53 genotypes were more popularly distributed in this region, which could provide the experimental basis for Chinese public health measures on cervical cancer prevention.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Tang, Liao, Hu, Shen, Wan and Wu.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies